Dow Up0.59% Nasdaq Down0.10%

Cytori Therapeutics, Inc. (CYTX)

0.51 Up 0.01(1.19%) 9:48AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121
United States - Map
Phone: 858-458-0900
Fax: 858-458-0994

Index Membership:N/A
Full Time Employees:115

Business Summary 

Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. In addition, Cytori Therapeutics, Inc. develops products in therapeutic areas, such as the treatment of thermal burns, and orthopedics and sports medicine indications, as well as specifically heart failure due to ischemic heart disease. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, clinics, tissue banks, stem cell banking companies, and researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Cytori Therapeutics, Inc.

Corporate Governance 
Cytori Therapeutics, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 5. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 2; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Marc H. Hedrick M.D., 51
Chief Exec. Officer, Pres and Director
Dr. Steven Kesten M.D., 56
Chief Medical Officer and Exec. VP
Mr. Tiago Girão ,
Chief Financial Officer and VP of Fin.
Mr. John W. Townsend ,
Chief Accounting Officer and Controller
Dr. John K. Fraser Ph.D., 53
Chief Scientist
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders